MCID: ANG025
MIFTS: 35

Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

MalaCards integrated aliases for Angioimmunoblastic Lymphadenopathy with Dysproteinemia:

Name: Angioimmunoblastic Lymphadenopathy with Dysproteinemia 38 76 53
Angioimmunoblastic with Dysproteinemia Lymphadenopathy 53

Classifications:



Summaries for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

MalaCards based summary : Angioimmunoblastic Lymphadenopathy with Dysproteinemia, also known as angioimmunoblastic with dysproteinemia lymphadenopathy, is related to food allergy and angioimmunoblastic t-cell lymphoma. An important gene associated with Angioimmunoblastic Lymphadenopathy with Dysproteinemia is IL5 (Interleukin 5), and among its related pathways/superpathways are Allograft rejection and Immune response Fc epsilon RI pathway. The drugs Vincristine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, lymph node and endothelial.

Wikipedia : 76 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Related Diseases for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Diseases related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 food allergy 30.6 IL13 IL5
2 angioimmunoblastic t-cell lymphoma 11.8
3 lymphoma 10.7
4 rheumatoid arthritis 10.3
5 autoimmune lymphoproliferative syndrome, type v 10.3
6 arthritis 10.3
7 b-cell lymphomas 10.3
8 sarcoma 10.3
9 pure red-cell aplasia 10.3
10 lymphosarcoma 10.3
11 bagassosis 10.2 IL5 IL6
12 multicentric castleman disease 10.2 IL5 IL6
13 castleman disease 10.2 IL5 IL6
14 cytokine deficiency 10.2 IL13 IL5
15 mesenteric lymphadenitis 10.2 IL5 IL6
16 respiratory syncytial virus infectious disease 10.2 IL13 IL5
17 nickel allergic contact dermatitis 10.2 IL13 IL5
18 paragonimiasis 10.2 IL13 IL5
19 radiculopathy 10.2 IL5 IL6
20 angiostrongyliasis 10.2 IL13 IL5
21 inflammatory bowel disease 4 10.2 IL13 IL5
22 apple allergy 10.2 IL13 IL5
23 strongyloidiasis 10.2 IL13 IL5
24 ascaris lumbricoides infection 10.2 IL13 IL5
25 latex allergy 10.2 IL13 IL5
26 eosinophilic meningitis 10.2 IL13 IL5
27 myositis 10.2
28 peripheral t-cell lymphoma 10.2
29 dermatomyositis 10.2
30 sclerosing cholangitis 10.2
31 synovitis 10.2
32 cholangitis 10.2
33 intestinal schistosomiasis 10.2 IL13 IL5
34 chronic tic disorder 10.2 IL13 IL5
35 chronic conjunctivitis 10.2 IL13 IL5
36 eosinophilic gastritis 10.2 IL13 IL5
37 vernal keratoconjunctivitis 10.2 IL13 IL5
38 urinary schistosomiasis 10.2 IL13 IL5
39 esophagitis, eosinophilic, 1 10.2 IL13 IL5
40 pollen allergy 10.2 IL13 IL5
41 enterobiasis 10.2 IL13 IL5
42 allergic contact dermatitis 10.2 IL5 TNF
43 cow milk allergy 10.2 IL5 TNF
44 scleritis 10.2 IL5 TNF
45 spinal cord injury 10.2 IL6 TNF
46 cardiac sarcoidosis 10.2 IL5 TNF
47 primary bacterial infectious disease 10.2 IL6 TNF
48 chorioamnionitis 10.2 IL6 TNF
49 autoimmune disease of central nervous system 10.2 IL6 TNF
50 autoimmune disease of musculoskeletal system 10.2 IL6 TNF

Graphical network of the top 20 diseases related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia:



Diseases related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Symptoms & Phenotypes for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Drugs & Therapeutics for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Drugs for Angioimmunoblastic Lymphadenopathy with Dysproteinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-22-7, 2068-78-2 5978
2
Ifosfamide Approved Phase 4,Phase 1,Phase 2,Early Phase 1 3778-73-2 3690
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 53-03-2 5865
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
7
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-02-2 5743
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 23214-92-8 31703
12
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
13
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 51-75-2 4033
14
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
16
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 31703
17
Pirarubicin Investigational Phase 4 72496-41-4
18
Isophosphamide mustard Phase 4,Phase 1,Phase 2,Early Phase 1 0
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
21 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
24 BB 1101 Phase 4,Phase 3,Phase 2,Early Phase 1
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
27 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
28 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
33 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
37 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Folate Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Vitamin B9 Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
45
alemtuzumab Approved, Investigational Phase 3,Phase 1,Phase 2 216503-57-0
46
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
47
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
48
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
49 Orange Approved Phase 3
50
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764

Interventional clinical trials:

(show top 50) (show all 254)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
4 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
14 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
15 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
16 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
17 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
18 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
19 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
20 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
21 Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL Recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
22 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Active, not recruiting NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
23 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
24 Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Not yet recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
25 Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
26 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
27 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
28 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
29 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
30 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
31 A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
32 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
33 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
34 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
35 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
36 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
37 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
38 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
39 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
40 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
41 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
42 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2 nelarabine
43 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
44 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
45 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
46 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
47 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
48 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
49 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
50 Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00039351 Phase 2 cyclophosphamide;prednisone;vincristine sulfate

Search NIH Clinical Center for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Angioimmunoblastic Lymphadenopathy with Dysproteinemia:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Anatomical Context for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

MalaCards organs/tissues related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia:

41
T Cells, Lymph Node, Endothelial, Bone, Heart, Eye, Spinal Cord

Publications for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Articles related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia:

(show top 50) (show all 59)
# Title Authors Year
1
Angioimmunoblastic lymphadenopathy with dysproteinemia: thoracic involvement. ( 15072329 )
2004
2
Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration. ( 12729371 )
2003
3
Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. ( 12624498 )
2003
4
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. ( 11408715 )
2001
5
Analysis of T-cell subpopulations in T-cell non-Hodgkin's lymphoma of angioimmunoblastic lymphadenopathy with dysproteinemia type by single target gene amplification of T cell receptor- beta gene rearrangements. ( 11337383 )
2001
6
Cytoplasmic cytokines in lymphoproliferative disorders: multiple cytokine production in angioimmunoblastic lymphadenopathy with dysproteinemia. ( 10953975 )
2000
7
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methotrexate and prednisone. ( 10942945 )
2000
8
A case of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) together with total atelectasis of a lung caused by lymphadenopathy and pleural effusion. ( 10736820 )
2000
9
Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological, and molecular analysis. ( 10890990 )
2000
10
Seropositive rheumatoid arthritis with dermatomyositis sine myositis, angioimmunoblastic lymphadenopathy with dysproteinemia-type T cell lymphoma, and B cell lymphoma of the oropharynx. ( 10782842 )
2000
11
The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. ( 10027729 )
1999
12
Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. ( 10492085 )
1999
13
Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment. ( 9554450 )
1998
14
Development of Epstein-Barr virus-associated B cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia. ( 9650454 )
1998
15
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia by local irradiation. ( 9646314 )
1998
16
Angioimmunoblastic lymphadenopathy with dysproteinemia--lack of a prognostic value of clear cell morphology. ( 9143398 )
1997
17
Clonal identification of trisomies 3, 5 and X in angioimmunoblastic lymphadenopathy with dysproteinemia by fluorescence in situ hybridization. ( 9086442 )
1997
18
Lymph node pathology in patients with a clinical diagnosis of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD): an analysis of 37 cases. ( 9251843 )
1997
19
CNS complications in a girl with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). ( 8892375 )
1996
20
Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2-chlorodeoxyadenosine. ( 9003160 )
1996
21
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. ( 8822958 )
1996
22
Angioimmunoblastic T-cell lymphoma (angioimmunoblastic lymphadenopathy with dysproteinemia [AILD]-type T-cell lymphoma) followed by Hodgkin's disease associated with Epstein-Barr virus. ( 8808302 )
1995
23
Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. ( 7919378 )
1994
24
Angioimmunoblastic lymphadenopathy with dysproteinemia and dermal T-cell lymphoma. ( 8082083 )
1994
25
Pure red cell aplasia associated with angioimmunoblastic lymphadenopathy with dysproteinemia. ( 8172198 )
1994
26
[Angioimmunoblastic lymphadenopathy with dysproteinemia and sclerosing cholangitis]. ( 8125036 )
1994
27
Detection of Epstein-Barr virus DNA and EBV-determined nuclear antigen in angioimmunoblastic lymphadenopathy with dysproteinemia type T cell lymphoma. ( 8183733 )
1993
28
Angioimmunoblastic lymphadenopathy with dysproteinemia. ( 8296199 )
1993
29
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. ( 1568181 )
1992
30
Detection of human cytomegalovirus antigen and DNA in lymph nodes and peripheral blood mononuclear cells of patients with angioimmunoblastic lymphadenopathy with dysproteinemia. ( 1316112 )
1992
31
Peripheral T-cell lymphoma of AILD (angioimmunoblastic lymphadenopathy with dysproteinemia) type involving gastrointestinal tract. A morphologic, phenotypic and genotypic study. ( 1314007 )
1992
32
Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) in a patient with food allergy. ( 1772108 )
1991
33
High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). ( 1790431 )
1991
34
Synovitis in angioimmunoblastic lymphadenopathy with dysproteinemia simulating rheumatoid arthritis. ( 2328036 )
1990
35
Angioimmunoblastic lymphadenopathy with dysproteinemia: report of a case in infancy with review of literature. ( 2701700 )
1989
36
NIH conference. Angioimmunoblastic lymphadenopathy with dysproteinemia. ( 3279895 )
1988
37
Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive "angioimmunoblastic lymphadenopathy with dysproteinemia-type" features. ( 3261178 )
1988
38
Angioimmunoblastic lymphadenopathy with dysproteinemia in Thailand. ( 3329519 )
1987
39
Angioimmunoblastic lymphadenopathy with dysproteinemia. Complete remission with cisplatin-based chemotherapy. ( 2449941 )
1987
40
Angioimmunoblastic lymphadenopathy with dysproteinemia, its position in T cell proliferative disorders. ( 2965846 )
1987
41
Proliferating cell population in angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) lesions analyzed by double immunoenzymatic staining and immunomolecular markers. ( 2965845 )
1987
42
Common karyotypic pattern in angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) and malignant lymphoma of peripheral T-cell origin with AILD features. ( 3502312 )
1987
43
Monoclonal hypergammaglobulinemia without malignant transformation in angioimmunoblastic lymphadenopathy with dysproteinemia. ( 3111261 )
1987
44
Monoclonal hypergammaglobulinemia without malignant transformation in angioimmunoblastic lymphadenopathy with dysproteinemia. ( 3752156 )
1986
45
Monoclonal hypergammaglobulinemia without malignant transformation in angioimmunoblastic lymphadenopathy with dysproteinemia. ( 3946445 )
1986
46
Spontaneous long-lasting remission in a young patient with angioimmunoblastic lymphadenopathy with dysproteinemia. ( 3924758 )
1985
47
Hodgkin's disease developing in a patient with angioimmunoblastic lymphadenopathy with dysproteinemia--a case report. ( 4024285 )
1985
48
Angioimmunoblastic lymphadenopathy with dysproteinemia. Circulating immune complexes and the review of 18 cases. ( 3978574 )
1985
49
Angioimmunoblastic lymphadenopathy with dysproteinemia in homosexual men with acquired immune deficiency syndrome. ( 6688715 )
1983
50
Angioimmunoblastic Lymphadenopathy with Dysproteinemia. Report of a case with pure red cell aplasia. ( 6819197 )
1982

Variations for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Expression for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Search GEO for disease gene expression data for Angioimmunoblastic Lymphadenopathy with Dysproteinemia.

Pathways for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Pathways related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 IL13 IL5 IL6 TNF
2
Show member pathways
12.36 IL13 IL5 TNF
3
Show member pathways
12.32 IL13 IL5 IL6 TNF
4
Show member pathways
12.2 IL5 IL6 TNF
5
Show member pathways
12.17 IL13 IL5 IL6
6
Show member pathways
11.97 IL13 IL5 IL6 TNF
7 11.96 IL13 IL6 TNF
8
Show member pathways
11.96 IL13 IL5 IL6 TNF
9
Show member pathways
11.85 IL13 IL5 IL6
10
Show member pathways
11.82 IL13 IL6 TNF
11 11.78 IL5 IL6 TNF
12 11.76 IL13 IL6 TNF
13 11.67 IL5 IL6 TNF
14 11.58 IL13 IL5 IL6
15 11.51 IL13 IL5 TNF
16 11.43 IL13 IL6 TNF
17 11.4 IL6 TNF
18 11.37 IL6 TNF
19 11.34 IL6 TNF
20 11.33 IL6 TNF
21 11.32 IL5 IL6
22 11.3 IL13 IL5
23 11.29 IL6 TNF
24 11.26 IL13 IL5 IL6 TNF
25 11.23 IL13 IL6 TNF
26 11.17 IL6 TNF
27 11.16 IL6 TNF
28 11.1 IL6 TNF
29 11.01 IL13 IL5
30 10.93 IL6 TNF
31 10.86 IL6 TNF
32 10.79 IL13 IL5 IL6 TNF
33 10.76 IL13 IL5 IL6 TNF
34 10.76 IL13 IL5 IL6 TNF
35 10.39 IL13 IL5 IL6 TNF

GO Terms for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

Biological processes related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.78 IL13 IL5 IL6 TNF
2 regulation of signaling receptor activity GO:0010469 9.71 IL13 IL5 IL6 TNF
3 positive regulation of interleukin-6 production GO:0032755 9.58 IL6 TNF
4 humoral immune response GO:0006959 9.58 IL6 TNF
5 negative regulation of fat cell differentiation GO:0045599 9.57 IL6 TNF
6 positive regulation of B cell proliferation GO:0030890 9.56 IL13 IL5
7 inflammatory response GO:0006954 9.56 IL13 IL5 IL6 TNF
8 positive regulation of JAK-STAT cascade GO:0046427 9.55 IL5 IL6
9 negative regulation of neurogenesis GO:0050768 9.54 IL6 TNF
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.54 IL5 IL6 TNF
11 positive regulation of chemokine production GO:0032722 9.52 IL6 TNF
12 microglial cell activation GO:0001774 9.51 IL13 TNF
13 positive regulation of glial cell proliferation GO:0060252 9.49 IL6 TNF
14 positive regulation of immunoglobulin secretion GO:0051024 9.46 IL5 IL6
15 positive regulation of podosome assembly GO:0071803 9.43 IL5 TNF
16 negative regulation of lipid storage GO:0010888 9.32 IL6 TNF
17 cytokine-mediated signaling pathway GO:0019221 9.26 IL13 IL5 IL6 TNF
18 positive regulation of neuroinflammatory response GO:0150078 9.16 IL6 TNF
19 positive regulation of smooth muscle cell proliferation GO:0048661 8.8 IL13 IL6 TNF

Molecular functions related to Angioimmunoblastic Lymphadenopathy with Dysproteinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL13 IL5 IL6 TNF

Sources for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....